Ключевые слова:
Oxidative stress; 8-OHdG; F2-isoprostanes; malondialdehyde; nephropathy; obese asthma; biomarkers; CKD.Библиографические ссылки
Arabi T, et al. Obesity-related kidney disease: mechanisms. Front Endocrinol. 2023; 14:1095211.
Arabi T., et al. adipokine effects on renal oxidative stress. Front Endocrinol. 2023.
ATS Scientific Statement: Obesity-related asthma and oxidative stress. Am J Respir Crit Care Med. 2024.
Cordiano R., et al. Malondialdehyde in allergy and metabolic disease. Antioxidants (Basel). 2023.
Graille M. Urinary 8-OHdG as a Biomarker for Oxidative Stress: Systematic Review. Int J Mol Sci. 2020;21.
Graille M., et al. (see ref 4) association of 8-OHdG with albuminuria.
Hojs NV, et al. Oxidative Stress Markers in Chronic Kidney Disease. Oxid Med Cell Longev. 2020.
Jung CY, et al. Novel biomarkers for diabetic kidney disease. Kidney Res Clin Pract. 2022.
Perdomo CM, et al. Adiposity-related disease framework. Rev Endocr Metab Disord. 2023.
Pradeep U, et al. Comprehensive Review of Advanced Biomarkers for Renal Disease. Biomarkers Med. 2024.
Recent reviews recommending trials of antioxidant strategies in CKD (2021–2025).
Rusu CC, et al. Malondialdehyde and outcomes in dialysis patients. Ren Fail. 2016.
Tooba R, et al. Obesity and Asthma: A Focused Review. Respir Med. 2022.
Various cohort studies linking F2-isoprostanes with CKD markers (2020-2024).
Wang N., et al. Oxidative stress in progression of diabetic nephropathy. Antioxidants (Basel). 2024.
Yin Y, et al. Oxidative Balance Score and CKD prevalence in NHANES 2007–2018 (n=13,373). Sci Rep. 2024.